Nurtec Odt (rimegepant) is a small molecule pharmaceutical. Rimegepant was first approved as Nurtec Odt on 2020-02-27. It is used to treat migraine disorders, migraine with aura, and migraine without aura in the USA. The pharmaceutical is active against calcitonin gene-related peptide type 1 receptor. Nurtec odt's patents are valid until 2039-03-25 (FDA).
|Trade Name||Nurtec Odt|
|Indication||migraine disorders, migraine with aura, migraine without aura|
|Drug Class||Calcitonin gene-related peptide receptor antagonists|